Why the study?
Does empagliflozin reduce cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes mellitus and high cardiovascular risk?
Does empagliflozin reduce cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes mellitus and high cardiovascular risk?
Empagliflozin's cardiovascular benefits in T2DM patients may be driven by physiological changes such as reduced cardiac workload and improved ventricular arterial coupling.
Offers a physiological rationale for established clinical benefits in heart failure; leaves open whether these hemodynamic.
Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.
No takes yet. Share an insight, caveat, or question.
Pham et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: